Genitourinary Cancer — VA Disability Rating (DC 7528)
Diagnostic Code 7528 · 38 CFR §4.115b
What Is It?
DC 7528 covers malignant neoplasms of the genitourinary system — prostate, bladder, kidney, ureter, urethra, and testicular cancers. It is one of the most heavily claimed codes in the schedule because several of these cancers are presumptively service connected for veterans with qualifying exposures, including bladder cancer for Camp Lejeune water contamination and for airborne hazards under the PACT Act, and prostate cancer for Agent Orange herbicide exposure. Unlike most codes in this section, DC 7528 has a percentage of its own, and only one: 100 percent. What governs everything after that is the note attached to it. The 100 percent evaluation continues beyond the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure, with a mandatory VA examination at the expiration of six months. Any change in evaluation based on that or any subsequent examination is subject to the provisions of 38 CFR §3.105(e), which is the procedure VA must follow before reducing a rating. If there has been no local reoccurrence or metastasis, the condition is rated on residuals as voiding dysfunction or renal dysfunction, whichever is predominant. Understanding that sequence is the whole game: the drop from 100 percent is scheduled, it is predictable, and the months before it are when the residual record either gets built or does not.
Rating Criteria
| Rating | Criteria |
|---|---|
| 100% | Malignant neoplasm of the genitourinary system. Note: following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the 100 percent rating shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of 38 CFR §3.105(e). If there has been no local reoccurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant. The 100 percent level also returns on the renal path at GFR less than 15 mL/min/1.73 m2, on regular routine dialysis, or as an eligible kidney transplant recipient. |
| 80% | Residual stage, renal dysfunction path: GFR 15 to 29 mL/min/1.73 m2 for at least 3 consecutive months during the past 12 months — relevant after nephrectomy or nephrotoxic chemotherapy. |
| 60% | Residual stage: urine leakage requiring the use of an appliance or absorbent materials changed more than 4 times per day — the maximum on the voiding side, and common after radical prostatectomy or cystectomy with urinary diversion. On the renal side, GFR 30 to 44 mL/min/1.73 m2 for at least 3 consecutive months during the past 12 months. |
| 40% | Residual stage: urinary frequency with a daytime voiding interval less than one hour or awakening to void five or more times per night; or urine leakage requiring absorbent materials changed 2 to 4 times per day. |
| 30% | Residual stage: obstructed voiding with urinary retention requiring intermittent or continuous catheterization; or renal dysfunction with GFR 45 to 59 mL/min/1.73 m2 for at least 3 consecutive months during the past 12 months. |
| 20% | Residual stage (after the 100 percent period ends): urinary frequency with a daytime voiding interval between one and two hours or awakening to void three to four times per night; or urine leakage requiring absorbent materials changed less than 2 times per day. |
| 10% | Residual stage: urinary frequency with a daytime voiding interval between two and three hours or awakening to void two times per night; or obstructed voiding with marked obstructive symptomatology plus post void residuals greater than 150 cc, peak flow less than 10 cc/sec, recurrent infections secondary to obstruction, or dilatation every 2 to 3 months. |
| 0% | Residual stage: no local reoccurrence or metastasis and no compensable residual — obstructive symptomatology requiring dilatation 1 to 2 times per year, or renal dysfunction with GFR 60 to 89 mL/min/1.73 m2 plus casts, structural abnormality, or an albumin/creatinine ratio of 30 mg/g or greater. A 0 percent evaluation keeps service connection intact for any later recurrence or decline. |
Evidence Needed
Two dates decide the timeline, so establish them in writing: the date of diagnosis and the date the last therapeutic procedure ended. The six-month clock in the note runs from cessation of treatment, not from diagnosis and not from the date of the decision. Get the oncology summary stating when chemotherapy, radiation, or surgery concluded. Then build the residual file during those six months rather than after: post-void residual and uroflowmetry, a pad count if you leak, a voiding diary, creatinine with calculated GFR if a kidney was removed or chemotherapy was nephrotoxic, and the operative and pathology reports. If you are claiming a presumption, the evidence is the pathology confirming the cancer type plus proof of qualifying service — dates and locations for herbicide exposure, or Camp Lejeune residence between August 1953 and December 1987. Surveillance imaging and PSA or cytology results document recurrence if it happens.
C&P Exam Tips
Go into the six-month examination prepared, because it is the appointment that sets your evaluation for the years afterward. Bring the residual documentation with you: the pad count, the voiding diary, the post-void residual, and the current GFR. Do not minimize. Veterans routinely tell that examiner they are doing fine because they are grateful to be past the cancer, and that report becomes the basis for the rating. Describe incontinence in changes per day, frequency in intervals and night-time counts, and erectile dysfunction plainly. If a kidney was removed, ask that renal function be evaluated with a current GFR, since the renal path reaches higher than the voiding path. If there is any evidence of recurrence or metastasis, say so immediately, because that keeps the 100 percent in place.
How to File
File on VA Form 21-526EZ naming the specific cancer and DC 7528, and attach the pathology report and the oncology treatment summary with start and end dates. If a presumption applies, say which one and supply the service evidence for it. Mark the date treatment ended on your own calendar and expect the mandatory examination six months later. In the months before it, get every residual documented in treatment records — incontinence, frequency, erectile dysfunction, kidney function, neuropathy, and any psychiatric condition — and file each as a separate issue rather than assuming they will be captured. If you receive a proposed reduction after that examination, read it against 38 CFR §3.105(e), which entitles you to notice and an opportunity to submit evidence before it takes effect.
Common Mistakes
The most damaging mistake is treating the six-month examination as a formality. It is a scheduled event with a known date, and a veteran who arrives with no residual documentation can go from 100 percent to 0 or 10 percent in a single appointment. The second is understating residuals out of relief or reticence; incontinence and erectile dysfunction are the two most underreported findings in these examinations and they are precisely what the residual evaluation is built from. The third is being evaluated on voiding dysfunction alone when a kidney was removed or chemotherapy damaged renal function, since the renal path reaches 80 and 100 percent while voiding stops at 60. The fourth is not knowing that any reduction must follow 38 CFR §3.105(e), which gives you a notice period and a right to respond that many veterans let expire.
Frequently Asked Questions
When exactly does the 100 percent rating end?
It does not end automatically. The note under DC 7528 provides that the 100 percent rating continues beyond the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure, with a mandatory VA examination at the expiration of six months. The evaluation only changes after that examination, and any change is subject to 38 CFR §3.105(e), which requires VA to propose the reduction, notify you, and give you an opportunity to respond before it takes effect. The clock runs from the end of treatment, not from diagnosis.
What happens if the cancer comes back?
The 100 percent evaluation applies again. The note conditions the shift to residuals on there having been no local reoccurrence or metastasis, so documented recurrence or spread restores the 100 percent basis. If you are found to have recurrence after being reduced, file immediately with the imaging, pathology, and oncology notes rather than waiting for a scheduled review, and ask that the effective date reflect when the recurrence was documented.
Is ongoing hormone therapy still active treatment?
This is a contested point worth raising rather than assuming. Androgen deprivation therapy for prostate cancer is antineoplastic treatment, and veterans have argued successfully that the six-month clock should run from the end of that therapy rather than from surgery or radiation. If you remain on hormone therapy, make sure the record says so clearly and ask the rater to address whether treatment has actually ceased. Get your oncologist to state in writing that the therapy is antineoplastic and ongoing.
How are residuals rated after the six months?
As voiding dysfunction or renal dysfunction, whichever is predominant. Voiding dysfunction offers three formulas — urine leakage to 60 percent, urinary frequency to 40 percent, and obstructed voiding to 30 percent. Renal dysfunction is graded on glomerular filtration rate through 30, 60, 80, and 100 percent. Erectile dysfunction, neuropathy, and psychiatric conditions are rated under their own codes as separate issues, so claim them by name rather than expecting them inside the residual evaluation.
Which genitourinary cancers are presumptive?
Prostate cancer is presumptive for veterans with qualifying herbicide exposure. Bladder cancer and kidney cancer are among the conditions presumptively associated with Camp Lejeune water contamination for service there between August 1953 and December 1987, and bladder cancer is also on the PACT Act list for burn pit and airborne hazard exposure. Presumptive status removes the need for a nexus opinion but not the need for evidence of qualifying service, so document the dates and locations carefully.